Loading...
Loading...
J&J's
JNJ Janssen Pharmaceutical
Companies today announced their intention not to enforce
the patents they own and control on the antiretroviral (ARV) drug darunavir
provided the darunavir product is medically acceptable and is used only in
resource-limited settings.^1 This announcement is intended to assure generic
manufacturers that they may manufacture high quality darunavir product used in
SSA and the LDCs without a concern that Janssen will accuse these activities
of infringing its darunavir patents.
This new policy anticipates a greater future need to supply affordable generic
versions of darunavir (brand name PREZISTA^®) for the treatment of people
living with HIV in the territory, and is consistent with the Company's focus
on access to medicines in those countries with the highest rates of HIV
infection and economic vulnerability.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in